Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump's new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

US President Donald Trump has signed an executive order aimed at reducing drug costs for Americans, by up to 80% immediately.

The move immediately hit Australia's pharmaceutical industry as 3 ASX pharmaceutical stocks crashed up to 10% shortly after the announcement.

Telix Pharmaceuticals Ltd (ASX: TLX) shares dropped 8.7% on Monday, to $24.47. The stock price has since recovered some losses, increasing 3.6% to $25.36 and has continued an upward trajectory today. It still has some way to go before it reaches the $29-mark seen earlier this month.

Similarly, Neuren Pharmaceuticals Ltd (ASX: NEU) shares dropped 9.56% at the close on Monday, to $12.02. The company share price has recovered some losses over the past 24 hours, rising 2.6% at the close yesterday. There are indications of another small increase today.

Clarity Pharmaceuticals Ltd (ASX: CU6) also followed the same trend. Its shares dropped 8.64% on Monday to $2.22 before rising 15.3% yesterday. The pharmaceuticals stock has experienced a steady decline since October last year before bottoming out in April.

What is Trump's executive order, and why is it affecting ASX pharmaceutical stocks?

As news.com reported:

What that means, in essence, is the US government will buy drugs at the lowest price they're being purchased for in other countries…Mr Trump is of the opinion that this will lead to lower prices in the United States, and that pharmaceutical companies will compensate by charging the rest of the world more.

The order, which has been described as a "game changer", casued an immediate drop of share prices for 3 ASX pharmaceutical stocks following fears that they will be forced to lower their drug prices. 

"Starting today, the United States will no longer subsidise the health care of foreign countries, which is what we were doing, we're subsidising others' health care, in countries where they pay a small fraction of what, for the same drug, that what we pay," US President Trump told reporters Monday at the White House. 

He said that big pharmaceutical companies will either have to abide by his new principle voluntarily. If not, he'll use the power of the federal government to ensure "we are paying the same price of other countries". 

The President tried to implement something similar during his first term in office, but was prevented by the courts. He slammed the idea as ineffective when Kamala Harris suggested it during last year's election campaign. Now he appears to have recommitted to the policy.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »